Articles tagged "Calcineurin"

2017 American Transplant Congress
M1 Macrophage-Induced Loss of KLF15 Promotes Chronic Podocyte Injury.
S. Han,^1,2 Y. Kim,¹ S. Lee,¹ H. Lee,^1,2 R.-H. Cha,² J. Lee,^1,2 J. Lee,² D. Kim,^1,2 Y. Kim,^1,2 S. Yang.^1,2
¹Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; ²Kidney Research Institute, Seoul National University, Seoul, Korea
Background: Krüppel-like factor 15 (KLF15), kidney-enriched transcription factor, is known to participate in the differentiation of podocyte. However, the implication of KLF15 in chronic podocyte…
2017 American Transplant Congress
Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.
K. Soliman, A. Posadas Salas, D. Taber.
Transplant, MUSC, Charleston, SC
There is strong evidence that both tacrolimus (FK) and mycophenolate (MMF) have improved outcomes in kidney transplantation; yet, the impact of exposure of these immunosuppressants…
2017 American Transplant Congress
Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial.
D. Hesselink,¹ N. Shuker,¹ J. Osinga,¹ M. Clahsen -van Groningen,² J. Damman,² C. Baan,¹ J. van de Wetering,¹ A. Rowshani,¹ J. Kal -van Gestel,¹ W. Weimar,¹ T. van Gelder,³ R. Bouamar.³
¹Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; ²Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; ³Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
While conversion from ciclosporin to everolimus is well documented, conversion from tacrolimus has been poorly studied. In this randomized-controlled trial the safety and tolerability of…
2017 American Transplant Congress
Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.
Y. Watarai,¹ S. Narumi,¹ M. Okada,¹ R. Kimura,¹ K. Hatazoe,¹ K. Futamura,¹ T. Yamamoto,¹ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ²Kidney Transplant Surgery, Aichi Medical University, Nagakute, Aichi, Japan
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…
2017 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial.
K. Unagami,¹ M. Okumi,² T. Hirai,² D. Toki,³ H. Shirakawa,⁴ T. Shimizu,² K. Omoto,⁵ M. Inui,³ H. Ishida,² K. Nitta,¹ K. Tanabe.²
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan; ³Urology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan; ⁴Urology, Ohkubo Hospital, Tokyo, Japan; ⁵Transplant Surgery, Toda Chuo General Hospital, Toda, Japan
Background:Tacrolimus (TAC)-based induction therapy appears to be the standard immunosuppressive regimen for most kidney transplantation recipients (KTRs). TAC is available as a twice-daily (TAC-BID) and…
2017 American Transplant Congress
Systemic Meta-Analysis: Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients?
K. Jayant,¹ I. Reccia,² J. Walton,¹ A. Sharma,³ A. Halawa.¹
¹Faculty of Health and Sciences, Institute of Learning and Teaching, University of Liverpool, Liverpool, United Kingdom; ²Department of Hepato-Pancreato-Biliary Surgery (HPB), Hammersmith Hospital, Imperial College, London, United Kingdom; ³Sheffield Teaching Hospitals, Sheffield Teaching Hospitals, Sheffield, United Kingdom
Aim: This meta-analysis focuses on the current evidence of renal graft functioning and graft survival following early conversion to mTOR inhibitors with or without CNI…
2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal^® with Prograf^® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
W. Arns,¹ A. Huppertz,¹ T. Rath,¹ S. Ziefle,¹ L. Rump,¹ A. Hansen,¹ D. Baeumer,² K. Budde,¹ L. Lehner,¹ T. Klein,¹ P. Schenker.¹
¹SparTacus Study Group, Cologne, Germany; ²Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…
2016 American Transplant Congress
IL-2 Therapy Restores the Impaired Function of Regulatory T Cells Induced by Calcineurin Inhibitors in Liver Transplantation.
G. Whitehouse, E. Gray, S. Mastoridis, E. Kodela, A. Sanchez-Fueyo, M. Martinez-Llordella.
Liver Science Department, King's College London, London, United Kingdom.
CD4+CD25+FOXP3+ regulatory T cells (Tregs) have an essential role in immune regulation and constitute a key target for cellular immunotherapies in transplantation. IL-2 is critical…
2016 American Transplant Congress
The Effect of Spironolactone on Calcineurininhibitor Induced Nephrotoxicity.
L. Mortensen,¹ H. Thiesson,¹ C. Bistrup,¹ F. Nielsen,³ U. Halekoh,² B. Jensen,³ N. Marcussen.⁴
¹Department of Nephrology, Odense University Hospital, Odense, Denmark; ²Department of Biostatistics, University of Southern Denmark, Odense, Denmark; ³Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; ⁴Department of Clinical Pathology, Odense University Hospital, Odense, Denmark.
Purpose: Evidence points towards activation of the mineralocorticoid receptor (MR) to be involved in CNI nephrotoxicity. The SPIREN trial was designed to test the hypothesis…
2016 American Transplant Congress
Impact of Low Dose Tacrolimus with Everolimus Regimen on Renal Pathology and T-Regulatory Cells in Kidney Transplant.
A. Shetty,¹ T. Opas,¹ J. Mathew,¹ V. Mas,² J. Leventhal,¹ N. Sustento-Reodica,¹ L. Gallon.¹
¹Northwestern University, Feinberg School of Medicine, Chicago, IL; ²University of Virginia, Charlottesville, VA.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…